What's Happening?
A recent study conducted by researchers at Flinders University in Australia has raised concerns about the use of quetiapine, a medication commonly prescribed off-label for sleep disorders such as insomnia. The study, published in the Annals of the American
Thoracic Society, found that while low-dose quetiapine can modestly improve sleep quality and reduce the severity of obstructive sleep apnea (OSA), it also significantly impairs alertness and driving performance the following day. The clinical trial involved 15 adults who spent two nights in a sleep laboratory, one after taking 50 milligrams of quetiapine and another after taking a placebo. Results showed that quetiapine reduced breathing interruptions during sleep and improved sleep efficiency, but also led to slower reaction times, more lapses in attention, and poorer steering control during a driving simulation task.
Why It's Important?
The findings of this study are significant as they challenge the growing belief that low-dose quetiapine is a harmless solution for sleep issues. The medication, originally approved for schizophrenia and bipolar disorder, is increasingly used for its sedative effects to treat insomnia and anxiety. However, the study highlights the potential risks associated with its use, particularly the impairment of next-day alertness and driving performance. This poses a serious safety risk, especially for individuals who may not feel particularly sleepy but still experience impaired functioning. The study calls for a shift in the management of sleep disorders, advocating for tailored treatments that address the underlying causes of sleep disruption rather than relying on sedative medications.
What's Next?
The study's authors and other scientists are advocating for a change in how sleep disorders are treated, emphasizing the need for personalized approaches that target the root causes of sleep issues. This could lead to a reevaluation of current prescribing practices for quetiapine and similar medications, potentially influencing guidelines and recommendations for treating sleep disorders. Healthcare providers may need to consider alternative therapies and interventions that do not carry the same risks of cognitive impairment and dependency. Additionally, further research may be conducted to explore other treatment options and to better understand the long-term effects of using quetiapine for sleep-related issues.
